Involvement of Cholinergic Pathway in Energy Homeostasis via Ventromedial Hypothalamic D2 Receptors

Document Type : Original Article (s)

Authors

1 PhD in Physiology, Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Neurophysiology Research Center, Urmia University of Medical Sciences, Urmia, Iran

3 MSc Student, Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Studies indicate that dopamine, particularly via D2 receptors (D2R), has an important role in energy homeostasis. Our previous study demonstrated that hypothalamic D2Rs, through dorsal vagus complex, are involved in the regulation of ghrelin secretion. In present study, we evaluated whether vagus cholinergic system could play a role in the regulation of leptin and glucose plasma levels by hypothalamic ventromedial nucleus (VMH) D2Rs?Methods: Canulation was performed into the VMH in Wistar rats (220-250 g). In experiment day, fasted rats (for 20-24 hours) received atropine (cholinergic antagonist, 5 mg⁄ kg subcutaneously) or saline. Thirty minutes later, D2R agonist (Quinpilroe, 0.5 µg) or antagonist (Sulpiride, 0.005 µg) and saline (0.5 µl) were injected into the VMH. Then, blood samples were collected 0, 30, and 60 minutes later, and plasma leptin and glucose levels were measured using enzyme-linked immunosorbent assay (ELISA) kit and glucose oxidase method, respectively.Findings: Plasma leptin significantly decreased in a time-dependent manner in atropine-Quinpirole group compared to control group (P < 0.001); while increase in glucose levels was time-dependently stable in atropine-Quinpirole group (P < 0.001). No significant change was observed in leptin levels in atropine-Sulpiride group compared to control group.Conclusion: VMHD2Rs exert their effects on the regulation of leptin and glucose levels, at least partly, via vagus cholinergic pathway.

Keywords

References

  1. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995; 83(7): 1197-209.
  2. Luo S, Luo J, Meier AH, Cincotta AH. Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport 1997; 8(16): 3495-9.
  3. Kok P, Roelfsema F, Frolich M, van PJ, Stokkel MP, Meinders AE, et al. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab 2006; 291(5): E1038-E1043.
  4. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 1999; 69(3): 160-6.
  5. Cincotta AH, Meier AH, Cincotta M, Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8(10): 1683-707.
  6. Kok P, Roelfsema F, Frolich M, van Pelt J, Meinders AE, Pijl H. Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women. J Clin Endocrinol Metab 2006; 91(8): 3236-40.
  7. Kim KS, Yoon YR, Lee HJ, Yoon S, Kim SY, Shin SW, et al. Enhanced hypothalamic leptin signaling in mice lacking dopamine D2 receptors. J Biol Chem 2010; 285(12): 8905-17.
  8. Mastronardi CA, Yu WH, Srivastava VK, Dees WL, McCann SM. Lipopolysaccharide-induced leptin release is neurally controlled. Proc Natl Acad Sci USA 2001; 98(25): 14720-5.
  9. Ghasemi M, Mehranfard N, Eliassi A, Alaei HA. Modulation of the plasma ghrelin level by intra-ventromedial hypothalamic microinjection of D2 receptors agonist and antagonist. Neuropsychiatry (London) 2018; 8(1): 89-95.
  10. Killgore WD, Ross AJ, Kamiya T, Kawada Y, Renshaw PF, Yurgelun-Todd DA. Citicoline affects appetite and cortico-limbic responses to images of high-calorie foods. Int J Eat Disord 2010; 43(1): 6-13.
  11. Sugino T, Yamaura J, Yamagishi M, Kurose Y, Kojima M, Kangawa K, et al. Involvement of cholinergic neurons in the regulation of the ghrelin secretory response to feeding in sheep. Biochem Biophys Res Commun 2003; 304(2): 308-12.
  12. Kiyici S, Basaran NF, Cavun S, Savci V. Central injection of CDP-choline suppresses serum ghrelin levels while increasing serum leptin levels in rats. Eur J Pharmacol 2015; 764: 264-70.
  13. Wu X, Gao J, Yan J, Owyang C, Li Y. Hypothalamus-brain stem circuitry responsible for vagal efferent signaling to the pancreas evoked by hypoglycemia in rat. J Neurophysiol 2004; 91(4): 1734-47.
  14. Verberne AJ, Sabetghadam A, Korim WS. Neural pathways that control the glucose counterregulatory response. Front Neurosci 2014; 8: 38.
  15. Ueda M, Tamaya N, Miura H, Kuzuya M, Hattori A, Muraguchi M, et al. Rise in plasma leptin levels after stimulation of hypothalamic cholinoceptive neurons by neostigmine in rats. Drugs Exp Clin Res 2001; 27(5-6): 185-92.
  16. de Leeuw van Weenen JE, Parlevliet ET, Schroder-van der Elst JP, van den Berg SA, Willems van DK, Romijn JA, et al. Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice. Exp Diabetes Res 2011; 2011: 928523.
  17. Kuo DY. Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats. J Biomed Sci 2002; 9(2): 126-32.
  18. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56(2): 164-70.
  19. Xu R, Parlow AF, Wang Y. The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor. Brain Res 2002; 939(1-2): 95-9.
  20. GURUN MS, Ilcol YO, Taga Y, Ulus IH. Hyperglycemia induced by intracerebroventricular choline: Involvement of the sympatho-adrenal system. Eur J Pharmacol 2002; 438(3): 197-205.
  21. Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E, Ulus IH. Intraperitoneal administration of CDP-choline and its cholinergic and pyrimidinergic metabolites induce hyperglycemia in rats: involvement of the sympathoadrenal system. Arch Physiol Biochem 2007; 113(4-5): 186-201.
  22. Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E, Ulus IH. Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations. Auton Autacoid Pharmacol 2008; 28(1): 41-58.
  23. Mason WT. Staining of the magnocellular nuclei of the rat hypothalamus by a monoclonal antibody directed against the alpha-subunit of the nicotinic cholinergic receptor. Neurosci Lett 1985; 59(1): 89-95.
  24. Michels KM, Meeker RB, Hayward JN. Differential distribution of muscarinic cholinergic and putative nicotinic cholinergic receptors within the hypothalamo-neurohypophysial system of the rat. Neuroendocrinology 1986; 44(4): 498-507.
  25. Maresca A, Supuran CT. Muscarinic acetylcholine receptors as therapeutic targets for obesity. Expert Opin Ther Targets 2008; 12(9): 1167-75.
  26. Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R, et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001; 410(6825): 207-12.
  27. Sharf R, Ranaldi R. Blockade of muscarinic acetylcholine receptors in the ventral tegmental area disrupts food-related learning in rats. Psychopharmacology (Berl) 2006; 184(1): 87-94.
Journal of Isfahan Medical School
Volume 36, Issue 504 - Serial Number 504
September and October 2019
Pages 1389-1394

Files

History

  • Receive Date: 16 March 2018
  • Revise Date: 06 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics